Lab scientists yesterday reported that for the first time they had taken skin cells from patients who had suffered heart failure and turned them into cells that could repair damaged cardiac muscle.

...it marks an important advance in the quest for replacement cells

The technique has so far been tested on rats and it could take up to a decade of problem-solving before trials can go ahead on humans, the scientists cautioned.

Even so, it marks an important advance in the quest for replacement cells to treat tissue affected by disease, said the scientists who developed the technique in Israel.

The research uses a method called human-induced pluripotent stem cells, or hiPSCs, a recently-discovered source that is viewed as an exciting and less controversial research alternative to embryonic stem cells.

It entails taking cells from a patient and introducing genes to the cell nucleus. Helped by a chemical “cocktail”, these genes act as switches which reprogramme the cells back to their versatile, youthful state.

The ultimate goal is that if a patient’s own cells are used as the replenishment source, they will be recognised as friendly by the immune system and not be attacked.

Recent studies have shown it is possible to derive hiPSCs from young and healthy people and that these are capable of transforming into heart cells.

But until now, hiPSCs could not be obtained from elderly and diseased patients. Nor have researchers been able to show that heart cells created from hiPSCs can integrate with existing heart tissue.

“What is new and exciting about our research is that we have shown that it’s possible to take skin cells from an elderly patient with advanced heart failure and end up with his own beating cells in a laboratory dish that are healthy and young,” said professor of cardiology Lior Gepstein in Haifa, Israel.

Sign up to our free newsletters

Get the best updates straight to your inbox:
Please select at least one mailing list.

You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.